Newcastle University

Publications

Year: 2012 2011 2010 2009 2008 2007 2006 2005 2004 2003 2002 2001 2000 1999 1998 1997 1996 1995 1994 1993 1992 1991 1990 1989 1988 1987 1986 1984 1983 1980 1979

• Missiaglia E, Williamson D, Chisholm J, Wirapati P, Pierron G, Petel F, Concordet JP, Thway K, Oberlin O, Pritchard-Jones K, Delattre O, Delorenzi M, Shipley J. PAX3/FOXO1 Fusion Gene Status is the Key Prognostic Molecular Marker in Rhabdomyosarcoma and Significantly Improves Current Risk Stratification. Journal of Clinical Oncology 2012, (epub ahead of print).
• Heer R, Glendinning RJ, Nesbitt CN, Pal D, Rix D, Menezes P, Johnson MI. Secondary haemorrhage following transurethral resection of bladder tumour — is it always related to infection?. British Journal of Medical and Surgical Urology 2012, (epub ahead of print).
• Sunter NJ, Scott K, Hills R, Grimwade D, Taylor S, Worrillow LJ, Fordham SE, Forster VJ, Jackson G, Bomken S, Jones G, Allan JM. A functional variant in the core promoter of the CD95 cell death receptor gene predicts prognosis in acute promyelocytic leukemia. Blood 2012, 119(1), 196-205.
• Cowell IG, Sondka Z, Smith K, Lee KC, Manville CM, Sidorczuk Lesthuruge M, Rance HA, Padget K, Jackson GH, Adachi N, Austin CA. A model for MLL translocations in therapy-related leukemia involving topoisomerase IIB mediated DNA strand breaks and gene proximity. Proceedings of the National Academy of Sciences 2012. In Press.
• Tudhope SJ, Wang CC, Petrie JL, Potts L, Malcomson F, Kieswich J, Yaqoob MM, Arden C, Hampson LJ, Agius L. A Novel Mechanism for Regulating Hepatic GlycogenSynthesis Involving Serotonin and Cyclin-Dependent Kinase-5. Diabetes 2012, 61(1), 49-60.
• Boyd KD, Ross FM, Chiecchio L, Dagrada GP, Konn ZJ, Tapper WJ, Walker BA, Wardell CP, Gregory WM, Szubert AJ, Bell SE, Child JA, Jackson GH, Davies FE, Morgan GJ, NCRI Haematology Oncology Studies. A novel prognostic model in myeloma based on co-segregating adverse FISH lesions and the ISS: analysis of patients treated in the MRC Myeloma IX trial. Leukemia 2012, 26(2), 349-355.
• Veeratterapillay R, Simren R, El-Sherif A, Johnson MI, Soomro N, Heer R. Accuracy of the revised 2010 TNM classification in predicting the prognosis of patients treated for renal cell cancer in the north east of England. Journal of Clinical Pathology 2012, 65(4), 367-371.
• Elattar A, Warburton KG, Mukhopadhyay A, Freer RM, Shaheen F, Cross PA, Plummer ER, Robson CN, Edmondson RJ. Androgen receptor expression is a biological marker for androgen sensitivity in high grade serous epithelial ovarian cancer. Gynecologic Oncology 2012, 124(1), 142-147.
• Robertson AGN, Krishnan A, Ward C, Pearson JP, Small T, Corris PA, Dark JH, Karat D, Shenfine J, Griffin SM. Anti-reflux surgery in lung transplant recipients: outcomes and effects on quality of life. The European Respiratory Journal 2012, 39(3), 691-697.
• Korshunov A, Remke M, Kool M, Hielscher T, Northcott PA, Williamson D, Pfaff E, Witt H, Jones DT, Ryzhova M, Cho YJ, Wittmann A, Benner A, Weiss WA, vonDeimling A, Scheurlen W, Kulozik AE, Clifford SC, Collins PV, Westermann F, Taylor MD, Lichter P, Pfister SM. Biological and clinical heterogeneity of MYCN-amplified medulloblastoma. Acta Neuropathologica 2012, 123(4), 515-527.
• Korshunov A, Remke M, Kool M, Hielscher T, Northcott PA, Williamson D, Pfaff E, Witt H, Jones DTW, Ryzhova M, Cho YJ, Wittmann A, Benner A, Weiss WA, von Deimling A, Scheurlen W, Kulozik AE, Clifford SC, Collins VP, Westermann F, Taylor MD, Lichter P, Pfister SM. Biological and clinical heterogeneity of MYCN-amplified medulloblastoma. Acta Neuropathologica 2012, 123(4), 515-527.
• Britton KM, Eyre R, Harvey IJ, Stemke-Hale K, Browell D, Lennard TWJ, Meeson AP. Breast Cancer, Side Population Cells and ABCG2 expression. Cancer Letters 2012, (epub ahead of print).
• Molyneux EM, Rochford R, Griffin B, Newton R, Jackson G, Menon G, Harrison CJ, Israels T, Bailey S. Burkitt's lymphoma. Lancet 2012, 379(9822), 1234-1244.
• Clifford SC. Cancer Genetics: Evolution after tumour spread. Nature 2012, 482(7386), 481-482.
• Nicholson L, Knight T, Matheson E, Minto L, Case M, Sanichar M, Bomken S, Vormoor J, Hall A, Irving J. Casitas B lymphoma mutations in childhood acute lymphoblastic leukemia. Genes, Chromosomes & Cancer 2012, 51(3), 250-256.
• Morgan GJ, Davies FE, Gregory WM, Bell SE, Szubert AJ, Coy NN, Cook G, Feyler S, Johnson PRE, Rudin C, Drayson MT, Owen RG, Ross FM, Russell NH, Jackson GH, Child JA, NCRI Haematological Oncology. Cyclophosphamide, thalidomide, and dexamethasone as induction therapy for newly diagnosed multiple myeloma patients destined for autologous stem-cell transplantation: MRC Myeloma IX randomized trial results. Haematologica 2012, 97(3), 442-450.
• Cerbinskaite A, Mukhopadhyay A, Plummer ER, Curtin NJ, Edmondson RJ. Defective homologous recombination in human cancers. Cancer Treatment Reviews 2012, 38(2), 89-100.
• Ptasinska A, Assi SA, Mannari D, James SR, Williamson D, Dunne J, Hoogenkamp M, Wu M, Care M, McNeill H, Cauchy P, Cullen M, Tooze RM, Tenen DG, Young BD, Cockerill PN, Westhead DR, Heidenreich O, Bonifer C. Depletion of RUNX1/ETO in t(8;21) AML cells leads to genome-wide changes in chromatin structure and transcription factor binding. Leukemia 2012, (epub ahead of print).
• Ptasinska A, Assi SA, Mannari D, James SR, Williamson D, Hoogenkamp M, Wu M, Care M, McNeill H, Cauchy P, Cullen M, Tooze RM, Tenen DG, Young BD, Cockerill PN, Westhead DR, Heidenreich O, Bonifer C. Depletion of RUNX1/ETO in t(8;21) AML cells leads to genome-wide changes in chromatin structure and transcription factor binding. Leukemia 2012, (epub ahead of print).
• Fiser K, Sieger T, Schumich A, Wood B, Irving J, Mejstrikova E, Dworzak MN. Detection and monitoring of normal and leukemic cell populations with hierarchical clustering of flow cytometry data. Cytometry Part A 2012, 81A(1), 25-34.
• Kim KP, Berrington-Gonzalez A, Pearce M, Salotti J, Parker L, McHugh K, Craft A, Lee C. Development of a database of organ doses for pediatric and young adult CT scans in the United Kingdom. Radiation Protection Dosimetry 2012, epub ahead of print.
• Kumar R, Drinnan M, Mehanna H, Paleri V. Efficacy of the two week wait referral system for head and neck cancer: A systematic review. The Annals of The Royal College of Surgeons of England 2012, 94(3), 101-105.
• Thathia TH, Ferguson S, Gautrey HE, van Otterdijk S, Hili M, Rand V, Moorman AV, Meyer S, Brown R, Strathdee G. Epigenetic inactivation of TWIST2 in acute lymphoblastic leukemia leads to increased proliferation, increased cell survival and resistance to chemotherapy. Haematologica 2012, 97(3), 371-378.
• Thathia SH, Ferguson S, Gautrey HE, van Otterdijk SD, Hili M, Rand V, Moorman AV, Meyer S, Brown R, Strathdee G. Epigenetic inactivation of TWIST2 in acute lymphoblastic leukemia modulates proliferation, cell survival and chemosensitivity. Haematologica 2012, 97(3), 371-378.
• Woolner AF, Davidson A, Skinner R, King D. Evaluation of Infection Control Advice for Patients at Risk of Chemotherapy-Induced Neutropenia in 2 Pediatric Oncology Centers: Cape Town, South Africa, and Newcastle-Upon-Tyne, UK. Pediatric Hematology & Oncology 2012, 29(1), 73-84.
• Arden C, Tudhope SJ, Petrie JL, Al-Oanzi ZH, Cullen KS, Lange AJ, Towle HC, Agius L. Fructose 2,6-bisphosphate is essential for glucose-regulated genetranscription of glucose-6-phosphatase and other ChREBP target genes inhepatocytes. Biochemical Journal 2012, 443(1), 111-123.
• Tavecchio M, Munck JM, Cano C, Newell DR, Curtin NJ. Further characterisation of the cellular activity of the DNA-PK inhibitor, NU7441, reveals potential cross-talk with homologous recombination. Cancer Chemotherapy and Pharmacology 2012, 69(1), 155-164.
• Sinclair JC, Davies KM, Venien-Bryan C, Noble MEM. Generation of protein lattices by fusing proteins with matching rotational symmetry. Nature Nanotechnology 2012, 6(9), 558-562.
• Bechmann LP, Gastaldelli A, Vetter D, Patman GL, Pascoe L, Hannivoort RA, Lee UE, Fiel I, Muñoz U, Ciociaro D, Buzzigoli E, Miele L, Hui KY, Bugianesi E, Burt AD, Day CP, Mari A, Agius L, Walker M, Friedman SL, Reeves HL. Glucokinase links Krüppel-like factor 6 to the regulation of hepatic insulin sensitivity and non alcoholic fatty liver disease. Hepatology 2012, 55(4), 1083-1093.
• Moorman AV, Schwab C, Ensor HM, Russell LJ, Morrison H, Jones L, Masic D, Patel B, Rowe JM, Tallman M, Goldstone AH, Fielding AK, Harrison CJ. IGH@ translocations, CRLF2 deregulation and micro-deletions in adolescents and adults with acute lymphoblastic leukemia (ALL). Journal of Clinical Oncology 2012. In Press.
• O'Neill KA, Bunch KJ, Vincent TJ, Spector LG, Moorman AV, Murphy MFG. Immunophenotype and Cytogenetic Characteristics in the Relationship Between Birth Weight and Childhood Leukemia. Pediatric Blood & Cancer 2012, 58(1), 7-11.
• Stone SJ, Paleri V, Staines KS. Internal carotid artery aneurysm presenting as dental and orofacial pain. Journal of Laryngology and Otology 2012. In Press.
• Cross P, Naik R, Patel A, Nayar A, Hemming J, Williamson S, Henry J, Edmondson RJ, Godfrey KA, Galaal K, Metin A, Lopes A. Intra-operative frozen section analysis for suspected early-stage ovarian cancer: 11 years of Gateshead Cancer Centre experience. BJOG 2012, 119(7), 896-897.
• Danielli R, Ridolfi R, Chiarion-Sileni V, Queirolo P, Testori A, Plummer R, Boitano M, Calabro L, De Rossi C, Di Giacomo AM, Ferrucci PF, Ridolfi L, Altomonte M, Miracco C, Balestrazzi A, Maio M. Ipilimumab in pretreated patients with metastatic uveal melanoma: safety and clinical efficacy. Cancer Immunology, Immunotherapy 2012, 61(1), 41-48.
• Marin D, Gabriel IH, Ahmad S, Foroni L, de Lavallade H, Clark R, O'Brien S, Sergeant R, Hedgley C, Milojkovic D, Khorashad JS, Bua M, Alsuliman A, Khoder A, Stringaris K, Cooper N, Davis J, Goldman JM, Apperley JF, Rezvani K. KIR2DS1 genotype predicts for complete cytogenetic response and survival in newly diagnosed chronic myeloid leukemia patients treated with imatinib. Leukemia 2012, 26(2), 296-302.
• Kool M, Korshunov A, Remke M, Jones DTW, Schlanstein M, Northcott PA, Cho YJ, Koster J, Schouten-van Meeteren A, van Vuurden D, Clifford SC, Pietsch T, von Bueren AO, Rutkowski S, McCabe M, Collins VP, Backlund ML, Haberler C, Bourdeaut F, Delattre O, Doz F, Ellison DW, Gilbertson RJ, Pomeroy SL, Taylor MD, Lichter P, Pfister SM. Molecular subgroups of medulloblastoma: an international meta-analysis of transcriptome, genetic aberrations, and clinical data of WNT, SHH, Group 3, and Group 4 medulloblastomas. Acta Neuropathologica 2012, 123(4), 473-484.
• Taylor MD, Northcott PA, Korshunov A, Remke M, Cho YJ, Clifford SC, Eberhart CG, Parsons DW, Rutkowski S, Gajjar A, Ellison DW, Lichter P, Gilbertson RJ, Pomeroy SL, Kool M, Pfister SM. Molecular subgroups of medulloblastoma: the current consensus. Acta Neuropathologica 2012, 123(4), 465-472.
• Ryan SL, Schwalbe EC, Cole M, Lu Y, Lusher ME, Megahed H, O'Toole K, Nicholson SL, Bognar L, Garami M, Hauser P, Korshunov A, Pfister SM, Williamson D, Taylor RE, Ellison DW, Bailey S, Clifford SC. MYC family amplification and clinical risk-factors interact to predict an extremely poor prognosis in childhood medulloblastoma. Acta Neuropathologica 2012, 123(4), 501-513.
• Gamble LD, Kees UR, Tweddle DA, Lunec J. MYCN sensitizes neuroblastoma to the MDM2-p53 antagonists Nutlin-3 and MI-63. Oncogene 2012, 31, 752-763.
• Hunter JE, Willmore E, Irving JAE, Hostomsky Z, Veuger SJ, Durkacz BW. NF-kappa B mediates radio-sensitization by the PARP-1 inhibitor, AG-014699. Oncogene 2012, 31(2), 251-264.
• Thomas L, Drinnan M, Basavaiah N, Mehanna H, Jones T, Paleri V. Open conservation partial laryngectomy for laryngeal cancer: A Systematic review of English language literature. Cancer Treatment Reviews 2012, 38(3), 203-211.
• Swallow VM, Allen D, Williams J, Smith T, Crosier J, Lambert H, Qizalbash L, Wirz L, Webb NJA. Pan-Britain, mixed-methods study of multidisciplinary teams teaching parents to manage children's long-term kidney conditions at home: Study protocol. BMC Health Services Research 2012, 12(1), 33.
• Curtin NJ. Poly(ADP-ribose) polymerase (PARP) and PARP inhibitors. Drug Discovery Today: Disease Models 2012, 9(2), e51-e58.
• Proctor SJ, Wilkinson J, Jones G, Watson GC, Lucraft HH, Mainou-Fowler T, Culligan D, Galloway MJ, Wood KM, McNally RJ, James PW, Goodlad JR. Prospective evaluation of treatment outcome in 175 patients with Hodgkin lymphoma (HL) aged 60 years or over: the SHIELD study. Blood 2012, (epub ahead of print).
• Sultan J, Griffin SM, Di Franco F, Kirby JA, Shenton BK, Seal CJ, Davis P, Viswanath YKS, Preston SR, Hayes N. Randomized clinical trial of omega-3 fatty acid-supplementedenteral nutrition versus standard enteral nutrition in patients undergoing oesophagogastric cancer surgery. British Journal of Surgery 2012, 99(3), 305-447.
• Challen C, Anderson JJ, Chrzanowska-Lightowlers ZMA, Lightowlers R, Lunec J. Recombinant human MDM2 oncoprotein shows sequence composition selectivity for binding to both RNA and DNA. International Journal of Oncology 2012, 40(3), 851-859.
• Travis LB, Ng AK, Allan JM, Pui CH, Kennedy AR, Xu XG, Purdy JA, Applegate K, Yahalom J, Constine LS, Gilbert ES, Boice JD. Second Malignant Neoplasms and Cardiovascular Disease Following Radiotherapy. Journal of the National Cancer Institute 2012, 104(5), 357-370.
• Pearce MS, Salotti JA, McHugh K, Kim KP, Craft AW, Lubin J, Ron E, Parker L. Socio-economic variation in CT scanning in Northern England, 1990-2002. BMC Health Services Research 2012, 12(1), 24.
• Rogers HA, Kilday JP, Mayne C, Ward J, Adamowicz-Brice M, Schwalbe EC, Clifford SC, Coyle B, Grundy RG. Supratentorial and spinal pediatric ependymomas display a hypermethylated phenotype which includes the loss of tumor suppressor genes involved in the control of cell growth and death. Acta Neuropathologica 2012, 123(5), 711-725.
• Chen T, Stephens PA, Middleton FK, Curtin NJ. Targeting the S and G2 checkpoint to treat cancer. Drug Discovery Today 2012, 17(5-6), 194-202.
• Ahmed ARH, Griffiths AB, Tilby MT, Westley BR, May FEB. TFF3 Is a Normal Breast Epithelial Protein and Is Associated with Differentiated Phenotype in Early Breast Cancer but Predisposes to Invasion and Metastasis in Advanced Disease. American Journal of Pathology 2012, 180(3), 904-916.
• Baumli S, Hole AJ, Noble MEM, Endicott JA. The CDK9 C-helix Exhibits Conformational Plasticity That May Explain the Selectivity of CAN508. ACS chemical biology 2012, [Epub ahead of print].
• Armstrong JL, Martin S, Illingworth NA, Jamieson D, Neilson A, Lovat PE, Redfern CPF, Veal GJ. The impact of retinoic acid treatment on the sensitivity of neuroblastoma cells to fenretinide. Oncology Reports 2012, 27(1), 293-298.
• Klusmann JH, Reinhardt D, Zimmermann M, Kremens B, Vormoor J, Dworzak M, Creutzig U, Klingebiel T. The role of matched sibling donor allogeneic stem cell transplantation in pediatric high-risk acute myeloid leukemia: results from the AML-BFM 98 study. Haematologica 2012, 97(1), 21-29.
• Shall S, Gaymes T, Farzaneh F, Curtin N, Mufti GJ. The use of PARP inhibitors in cancer therapy: use as adjuvant with chemotherapy or radiotherapy; use as a single agent in susceptible patients; techniques used to identify susceptible patients. In: Tulin, A, ed. Poly(ADP-ribose) Polymerase: Methods and Protocols. New York, USA: Humana Press, Inc, 2012, pp.239-66.
• Jarvis IWH, Meczes EL, Thomas HD, Edmondson RJ, Veal GJ, Boddy AV, Ottley CJ, Pearson DG, Tilby MJ. Therapy induced carboplatin-DNA adduct levels in human ovarian tumours in relation to assessment of adduct measurement in mouse tumours. Biochemical Pharmacology 2012, 83(1), 69-77.
• Eiermann W, Bergh J, Cardoso F, Conte P, Crown J, Curtin NJ, Gligorov J, Gusterson B, Joensuu H, Linderholm BK, Martin M, Penault-Llorca F, Pestalozzi BC, Razis E, Sotiriou C, Tjulandin S, Viale G. Triple negative breast cancer: proposals for a pragmatic definition and implications for patient management and trial design. Breast 2012, 21(1), 20-26.
• Paleri V, Carding P, Drinnan M, Kelly C, Welch AR, Wilson JA. Voice outcomes following concurrent Chemoradiotherapy for advanced non-laryngeal head and neck cancer: a prospective study. Head and Neck 2012, (epub ahead of print).